Lund, Sweden

Mats Erntell

This inventor holds 1 USPTO granted patent. Top assignee: Hightech Receptor Ab. Active years: 1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mats Erntell. Retrieved from https://idiyas.com/inventor/mats-erntell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mats Erntell, Inventor in Lund, Sweden.

Introduction

Mats Erntell is an inventor associated with Lund, Sweden, and Hightech Receptor AB. His patent work includes an invention concerning Protein L and its immunoglobulin-binding subfragments.

Latest Patents

Erntell is credited with 1 patent: “Protein L and subfragments thereof, with immunoglobulin binding.” The invention describes Protein L and subfragments that bind immunoglobulins from different species and across all immunoglobulin classes. It also covers methods for preparing the protein and its subfragments, a reagent kit, a pharmaceutical composition, and strain 312 of *P. magnus*. The preparation process involves treating *P. magnus* 312 with proteolytic enzymes or mutanolysin.

Career Highlights

Erntell’s listed patent reflects work on a protein with potential applications in immunoglobulin binding and related research and pharmaceutical preparations. He is associated with Hightech Receptor AB.

Collaborations

His listed coworkers include Lars Bjorck and Erling Myhre.

Conclusion

Mats Erntell’s recorded invention focuses on Protein L and its immunoglobulin-binding properties, highlighting his contribution to biotechnology-related patent work.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…